Skip to content

Study · Measured the body's own peptide · 2009

6 results

Elevation of intracellular cyclic AMP inhibits NF-kappaB-mediated thymosin beta4 expression in melanoma cells.

Kim A, Son M, Kim KI, Yang Y, Song EY, Lee HG, Lim JS

Experimental cell research3 Jun 2009Cited by 18 (Europe PMC)

PMID19500569 (opens in a new tab)DOI10.1016/j.yexcr.2009.05.024 (opens in a new tab)PepBankPUB-19500569
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01LabEndogenous levelIn vitro (cells)Mechanism

    In murine B16F10 melanoma cells, the cAMP-inducing compounds alpha-MSH and IBMX significantly suppressed the cell's own thymosin beta4 expression.

    In plain wordsIn mouse melanoma cells, alpha-MSH and IBMX lowered the body's own thymosin beta4 expression.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseThymosin beta4 expression after alpha-MSH or IBMX
    Study

    mousen: not reported in source

    B16F10 murine melanoma cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    We found that treatment with the cAMP-inducing compounds alpha-MSH (alpha-melanocyte stimulating hormone) and IBMX (3-isobutyl-1-methylxanthine) significantly suppressed Tbeta4 expression and regulated EMT-associated genes through the suppression of NF-kappaB activation in B16F10 cells.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02LabEndogenous levelIn vitro (cells)Mechanism

    In murine B16F10 melanoma cells, alpha-MSH and IBMX suppressed NF-kappaB activation, through which they suppressed the cell's own thymosin beta4 expression.

    In plain wordsIn mouse melanoma cells, alpha-MSH and IBMX lowered NF-kappaB activity, which went with lower levels of the body's own thymosin beta4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseNF-kappaB activation after alpha-MSH or IBMX
    Study

    mousen: not reported in source

    B16F10 murine melanoma cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    We found that treatment with the cAMP-inducing compounds alpha-MSH (alpha-melanocyte stimulating hormone) and IBMX (3-isobutyl-1-methylxanthine) significantly suppressed Tbeta4 expression and regulated EMT-associated genes through the suppression of NF-kappaB activation in B16F10 cells.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone4

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 03AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Activity measurement

    In animal experiments, alpha-MSH- or IBMX-treated B16F10 melanoma cells had decreased metastatic potential compared with untreated control cells.

    In plain wordsIn mice, melanoma cells treated with alpha-MSH or IBMX spread less than untreated cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseMetastatic potential of alpha-MSH- or IBMX-treated melanoma cells
    Study

    mousen: not reported in source

    Mouse metastasis model
    Comparator
    Untreated control cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In animal experiments, the metastatic potential of the alpha-MSH- or IBMX-treated B16F10 melanoma cells was decreased compared to untreated control cells.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    In B16F10 melanoma cells, cAMP elevation, with decreased thymosin beta4 expression, inhibited in vitro invasiveness.

    In plain wordsIn mouse melanoma cells, raising cAMP lowered thymosin beta4 and reduced the cells' ability to invade.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIn vitro invasiveness after cAMP elevation
    Study

    mousen: not reported in source

    B16F10 murine melanoma cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Along with decreased Tbeta4 expression, the in vitro invasiveness and anchorage-independent growth in a semi-solid agar of these cells were also inhibited.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    In B16F10 melanoma cells, cAMP elevation, with decreased thymosin beta4 expression, inhibited anchorage-independent growth in semi-solid agar.

    In plain wordsIn mouse melanoma cells, raising cAMP lowered thymosin beta4 and reduced growth in semi-solid agar.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseAnchorage-independent growth after cAMP elevation
    Study

    mousen: not reported in source

    B16F10 murine melanoma cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Along with decreased Tbeta4 expression, the in vitro invasiveness and anchorage-independent growth in a semi-solid agar of these cells were also inhibited.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 06LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In B16F10 melanoma cells, elevated intracellular cAMP suppressed thymosin beta4 expression and reduced MMP-9 activity.

    In plain wordsIn mouse melanoma cells, raising cAMP lowered thymosin beta4 and reduced MMP-9 activity.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseMMP-9 activity after cAMP elevation
    Study

    mousen: not reported in source

    B16F10 murine melanoma cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Collectively, our data demonstrate that elevated intracellular cAMP significantly suppresses Tbeta4 expression and reduces MMP-9 activity, which leads to decreased metastatic potential.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.